SAB Biotherapeutics Inc. (SABS)

NASDAQ: SABS · IEX Real-Time Price · USD
1.92
-0.12 (-5.88%)
May 20, 2022 4:30 PM EDT - Market closed

Income Statement (Trailing)

Millions USD. Fiscal year is Jan - Dec.
Period Ended2022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302019-12-31
Revenue
-60.88-78.36-55.24-3.44
Revenue Growth (YoY)
-10.21%-2176.74%----
Gross Profit
-60.88-78.36-55.24-3.44
Selling, General & Admin
-17.09-10.09-6.77-4.1
Research & Development
-57.18-51.79-27.91-8.02
Operating Expenses
-74.27-61.89-34.68-12.12
Operating Income
--13.39-16.47-20.56--8.67
Interest Expense / Income
-0.29-0.33-0.47-0.43
Other Expense / Income
03.460-0.690-0.030-0.12
Pretax Income
0-17.14016.84020.120-8.99
Net Income
--17.14-16.84-20.12--8.99
Net Income Common
--17.14-16.84-20.12--8.99
Shares Outstanding (Basic)
4327353526253535
Shares Outstanding (Diluted)
-27-35-27-35
Shares Change
-1.21%-0.00%----
EPS (Basic)
--0.63-0.72-0.79--0.26
EPS (Diluted)
--0.63-0.67-0.74--0.26
Free Cash Flow Per Share
--0.26--0.10--0.11--0.28
Gross Margin
-100.00%-100.00%-100.00%-100.00%
Operating Margin
--22.00%-21.02%-37.22%--252.01%
Profit Margin
--28.16%-21.49%-36.42%--261.09%
Free Cash Flow Margin
--11.80%--4.60%--4.92%--285.41%
EBITDA
--15.2-18.08-21.14--8.23
EBITDA Margin
--24.96%-23.08%-38.26%--239.25%
EBIT
--16.85-17.16-20.59--8.56
EBIT Margin
--27.68%-21.90%-37.27%--248.64%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).